Explore

Trendline Trendline
Selagine Plasma Develops Pooled Plasma Eye Drops for Dry Eye Disease

Selagine Plasma Develops Pooled Plasma Eye Drops for Dry Eye Disease

Selagine Plasma Develops Pooled Plasma Eye Drops for Dry Eye Disease
Rapid Read Rapid Read
Vistagen Achieves Key Safety Milestone in Fasedienol Clinical Program for Social Anxiety Disorder

Vistagen Achieves Key Safety Milestone in Fasedienol Clinical Program for Social Anxiety Disorder

Vistagen, a biopharmaceutical company, has announced that its clinical program for fasedienol nasal spray has met the minimum patient exposure recommendations set by the International Council for Harmonisation (ICH) E1 guidelines. These guidelines are crucial for drugs intended for long-term treatment of non-life-threatening conditions. As of May 31, 2026, over 1,500 subjects have received at least one exposure to fasedienol, with more than 300 subjects exposed for at least six months and over 100 subjects for twelve months. This achievement is part of Vistagen's ongoing Phase 3 clinical trials, PALISADE-3 and PALISADE-4, which aim to evaluate the effectiveness of fasedienol for the acute treatment of social anxiety disorder. The company is optimistic about the drug's potential, noting its well-tolerated nature in completed trials. Topline results from the PALISADE-4 trial are expected in the second quarter of 2026, with Phase 2 Repeat Dose study results anticipated in the third quarter.
Trendline Trendline
N-Zyme Biomedical Initiates Phase 2 Trial for Pepsin Inhibitor in Reflux Disease

N-Zyme Biomedical Initiates Phase 2 Trial for Pepsin Inhibitor in Reflux Disease

N-Zyme Biomedical Initiates Phase 2 Trial for Pepsin Inhibitor in Reflux Disease
Rapid Read Rapid Read
Calibr-Skaggs Advances CLF065 Therapy for IBD Patients, Targeting Intestinal Lining Repair

Calibr-Skaggs Advances CLF065 Therapy for IBD Patients, Targeting Intestinal Lining Repair

The Calibr-Skaggs Institute for Innovative Medicines has announced the advancement of CLF065, a long-acting GLP-2 receptor agonist, into Phase 2 clinical trials for inflammatory bowel diseases (IBD), specifically chronic pouchitis and Crohn's disease. Chronic pouchitis is a common complication following J-pouch surgery in ulcerative colitis patients, affecting up to 30% of the 200,000 individuals in the U.S. with an ileal pouch. Current treatments focus on reducing inflammation, but CLF065 aims to repair the damaged intestinal lining, addressing epithelial barrier dysfunction. The therapy, developed using Calibr-Skaggs' proprietary stapled-peptide technology, has shown promise in early trials, demonstrating a sustained increase in plasma citrulline, a biomarker of intestinal mucosal growth.
Rapid Read Rapid Read
Calibr-Skaggs Advances CLF065 Therapy into Phase 2 IBD Studies Targeting Gut Lining Regeneration

Calibr-Skaggs Advances CLF065 Therapy into Phase 2 IBD Studies Targeting Gut Lining Regeneration

The Calibr-Skaggs Institute for Innovative Medicines has announced the advancement of CLF065, a long-acting GLP-2 receptor agonist, into two Phase 2 studies for inflammatory bowel diseases (IBD). This therapy aims to address epithelial barrier dysfunction, a key contributor to IBD, by supporting the integrity and regeneration of the gut lining. Unlike current treatments that primarily focus on reducing inflammation, CLF065 offers a dual-mechanism approach to achieve mucosal healing. The first patient has been enrolled in a study for chronic pouchitis, and an IND application has been filed for a study in Crohn's disease. The therapy, developed using Calibr-Skaggs' proprietary technology, has shown promise in early trials, demonstrating a potential for once-monthly dosing.
Trendline Trendline
Vistagen Achieves Key Safety Milestone in Fasedienol Clinical Program for Social Anxiety Disorder

Vistagen Achieves Key Safety Milestone in Fasedienol Clinical Program for Social Anxiety Disorder

Vistagen Achieves Key Safety Milestone in Fasedienol Clinical Program for Social Anxiety Disorder
Trendline Trendline
Amylyx Pharmaceuticals to Present Research on Post-Bariatric Hypoglycemia at ENDO 2026

Amylyx Pharmaceuticals to Present Research on Post-Bariatric Hypoglycemia at ENDO 2026

Amylyx Pharmaceuticals to Present Research on Post-Bariatric Hypoglycemia at ENDO 2026
Trendline Trendline
Eli Lilly Gains FDA Approval for Ebglyss Eczema Drug with New Maintenance Dosing

Eli Lilly Gains FDA Approval for Ebglyss Eczema Drug with New Maintenance Dosing

Eli Lilly Gains FDA Approval for Ebglyss Eczema Drug with New Maintenance Dosing
Rapid Read Rapid Read
Life Biosciences Administers First Cellular Reprogramming Injection in Human Eye to Combat Aging

Life Biosciences Administers First Cellular Reprogramming Injection in Human Eye to Combat Aging

Life Biosciences, a Boston-based company, has initiated a groundbreaking trial by administering a cellular 'reprogramming' injection into the eye of a glaucoma patient. This experimental procedure aims to rejuvenate old cells, making them behave like young ones. The trial, which is in its early stages and approved by the FDA, involves fewer than 20 participants across various U.S. locations, including Boston, New York, Los Angeles, and Charleston. The therapy utilizes three of the four 'Yamanaka factors,' proteins known for their role in cellular reprogramming, while omitting the one associated with cancer risk. The process is controlled by a daily doxycycline pill, allowing for the therapy to be paused if safety concerns arise. This trial is a cautious step towards potential whole-body treatments that could extend healthy lifespans.
Rapid Read Rapid Read
Amylyx Pharmaceuticals to Present Research on Post-Bariatric Hypoglycemia at ENDO 2026

Amylyx Pharmaceuticals to Present Research on Post-Bariatric Hypoglycemia at ENDO 2026

Amylyx Pharmaceuticals, Inc. has announced its participation in the Endocrine Society’s Annual Meeting (ENDO 2026) in Chicago, where it will present two significant poster presentations. The first presentation will focus on the burden of post-bariatric hypoglycemia (PBH) in the U.S., highlighting its impact on healthcare resources, economic factors, and quality of life. The second presentation will discuss the design considerations for the Phase 3 LUCIDITY clinical trial of avexitide, a glucagon-like peptide-1 (GLP-1) receptor antagonist being investigated for PBH treatment. Avexitide has shown promise in reducing hypoglycemic events in previous trials and has received several designations from the FDA, including Breakthrough Therapy and Orphan Drug Designations.
Rapid Read Rapid Read
Amylyx Pharmaceuticals Highlights Post-Bariatric Hypoglycemia Research at ENDO 2026

Amylyx Pharmaceuticals Highlights Post-Bariatric Hypoglycemia Research at ENDO 2026

Amylyx Pharmaceuticals has announced its participation in the Endocrine Society's Annual Meeting (ENDO 2026) with two poster presentations. The presentations focus on post-bariatric hypoglycemia (PBH), a condition affecting individuals who have undergone bariatric surgery. The first presentation examines the healthcare burden and quality of life impacts of PBH in the U.S., while the second discusses the design of the Phase 3 LUCIDITY trial for avexitide, a GLP-1 receptor antagonist being developed to treat PBH. Avexitide has shown promise in reducing hypoglycemic events in clinical trials and has received several FDA designations, including Breakthrough Therapy and Orphan Drug status.
Trendline Trendline
TSLP Inhibitors Market Projected to Grow Significantly by 2036 Due to Expanding Therapeutic Applications

TSLP Inhibitors Market Projected to Grow Significantly by 2036 Due to Expanding Therapeutic Applications

TSLP Inhibitors Market Projected to Grow Significantly by 2036 Due to Expanding Therapeutic Applications